Inventor · disambiguated record
Bradley M. Lunde
Also filed as: LUNDE BRADLEY · LUNDE BRADLEY M
22 granted patents·39 pending applications·63 citations·filing 2014–2025
94Inventor score
Files withDRAGONFLY THERAPEUTICS INC44SANOFI SA9PIERIS PHARMACEUTICALS GMBH4DAIICHI SANKYO CO LTD2CULLINAN ONCOLOGY INC1
Top patents by PatentIndex Score
61 records- 0197US11939384B1Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Mar 26, 2024·9 cites·16 claims
- 0296US11884733B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Jan 30, 2024·10 cites·14 claims
- 0395US9884898B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Feb 6, 2018·17 cites·20 claims
- 0494US12129300B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Oct 29, 2024·1 cites·8 claims
- 0591US11884732B2Proteins binding HER2, NKG2D and CD16DRAGONFLY THERAPEUTICS INC·Filed 2018·Granted Jan 30, 2024·6 cites·15 claims
- 0687US12384847B2Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 12, 2025·2 cites·20 claims
- 0787US12264200B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Apr 1, 2025·0 cites·18 claims
- 0886US2025019444A1Antibody variable domains targeting the nkg2d receptorDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0982US10400016B2Proteins specific for calcitonin gene-related peptidePIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Sep 3, 2019·4 cites·25 claims
- 1080US2025154261A1Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1179US12275791B2Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Apr 15, 2025·1 cites·6 claims
- 1279US12215157B2Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2025·1 cites·40 claims
- 1378US10329334B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Jun 25, 2019·1 cites·13 claims
- 1478US10118952B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Nov 6, 2018·1 cites·15 claims
- 1578US10072056B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Sep 11, 2018·1 cites·18 claims
- 1678US10065998B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Sep 4, 2018·1 cites·18 claims
- 1776US12384851B2Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 12, 2025·1 cites·30 claims
- 1876US2023391877A1Multispecific binding proteins targeting ceaDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1976US2023357409A1Proteins binding nkg2d, cd16 and nectin4DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2075US11034737B2Proteins specific for calcitonin gene-related peptidePIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Jun 15, 2021·1 cites·17 claims
- 2175US10947284B2Fusion moleculesPIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Mar 16, 2021·1 cites·22 claims
- 2275US10316071B2Fusion moleculesSANOFI SA·Filed 2016·Granted Jun 11, 2019·2 cites·15 claims
- 2375US2023227562A1Combination therapy of cancer involving multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2475US2023303702A1Combination therapy of cancer involving multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2574US12378318B2Proteins binding NKG2D, CD16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 5, 2025·1 cites·11 claims
- 2674US2024228625A1Proteins binding her2, nkg2d and cd16DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2772US2024018266A1Proteins binding cd123, nkg2d and cd16DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2871US2022380459A1Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2969US9150629B2Human tear lipocalins which bind PCSK9 and methods of use thereofPIERIS AG·Filed 2014·Granted Oct 6, 2015·1 cites·56 claims
- 3066US10927154B2Multi-specific polypeptide useful for localized tumor immunomodulationPIERIS PHARMACEUTICALS GMBH·Filed 2015·Granted Feb 23, 2021·1 cites·6 claims
- 3166US2021292420A1Proteins binding nkg2d, cd16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3266US2018371038A1Novel proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2018·Application pending·0 cites
- 3366US2018371037A1Novel proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2018·Application pending·0 cites
- 3466US2018346532A1Novel proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2018·Application pending·0 cites
- 3565US2021130474A1Multispecific binding proteins targeting caix, ano1, mesothelin, trop2, or claudin-18.2DRAGONFLY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3663US2022089760A1Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3763US2025206827A1Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3859US2021261668A1Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1DRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3958US2021130496A1Multispecific binding proteins targeting ceaDRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4056US2020277383A1Proteins binding nkg2d, cd16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4153US2020002436A1Proteins binding cd123, nkg2d and cd16DRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4252US2020216544A1Proteins binding nkg2d, cd16, and egfr, hla-e, ccr4, or pd-l1DRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4351US2021206859A1Proteins binding nkg2d, cd16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4450US9598476B2Nucleic acid molecules encoding muteins of human tear lipocalin which bind PCSK9DAIICHI SANKYO CO LTD·Filed 2015·Granted Mar 21, 2017·0 cites·51 claims
- 4550US2021363261A1Protein binding nkg2d, cd16 and a fibroblast activation proteinDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4650US2017173112A1Novel binding proteins for pcsk9DAIICHI SANKYO CO LTD·Filed 2017·Application pending·0 cites
- 4746US2021214436A1Multi-specific binding proteins and improvements thereonDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4846US2023032087A1Anti-serum albumin antibodiesCULLINAN ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 4946US2021238290A1Proteins binding nkg2d, cd16 and p-cadherinDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 5045US2020165344A1Proteins binding nkg2d, cd16 and flt3DRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
Showing the top 50 of 61 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →